Antibody Drug Conjugate Market Analysis and Growth 2018 - 2023

by vinit on Jun 9, 2021 Sports & Recreation 314 Views

Market Scope

Market Research Future (MRFR) assessed the global antibody drug conjugate market 2021 over the analysis period. Over the evaluation tenure (from 2017 to 2023), the antibody drug conjugate market is expected to expand at 19% CAGR. By 2023, the antibody drug conjugate market can garner considerable revenue.

Market Drivers and Restrains

Antibody drug conjugates is gaining reputation as the new age of therapeutic agents for treating cancer. The targeting specific advantage offered by antibody drug conjugates and the cytotoxic nature of drugs that can kill cancer cells are observed to contribute to the growing demand for antibody drug conjugate. The emergence of antibody drug conjugate as the ideal treatment of different forms of cancers can underpin the expansion of the market. The efficacy of administration of antibody drug conjugate and their high success rate are other causes that can favor the expansion of the market over the analysis period.

The ongoing adoption of advanced medical technology and inclination of physicians towards the application of cytotoxic drug is boosting the demand for antibody drug conjugate drugs. On the contrary, high expense for procedures and drop in fund can restraints the antibody drug conjugate market in the years to come.

Regional Assessment of Antibody Drug Conjugate Market

In North America, the rapid adoption of disruptive medical technology for a large patient population can prompt the expansion of antibody drug market in the near future. The upsurge of the antibody drug conjugates market can be attributed to the rise in number of obese adults and children, and increase in number of people in the ageing group.

The robust medical and research infrastructure in North America supports preclinical research and increase in research undertakings for antibody therapies and the adoption of advanced drug discoveries for oncology diseases can underpin the market growth in the near future. In addition, the collaboration between research institutes, biotechnology, and biopharmaceuticals companies, can add to the market rise in the review period.

Antibody Drug Conjugate Market Key Players

Seattle Genetics (US), AbbVie Inc. (US), Agensys, Inc. (US), Bayer HealthCare (Germany), Progenics Pharmaceuticals (US), Astellas Pharma/Agensys (Japan), Mersana Therapeutics (US), Heidelberg Pharma (Germany), Synthon (US), ImmunoGen, Inc. (US), Genentech (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Antikor (UK), Oxford BioTherapeutics (US), Immunomedics (US), Pfizer Inc. (US), Millennium Pharmaceuticals (US), and Celldex Therapeutics (US) are some reputed companies in the antibody drug conjugate market that are listed by MRFR in the latest report.


Article source:



Overall Rating:


No comments have been left here yet. Be the first who will do it.

captchaPlease input letters you see on the image.
Click on image to redraw.


Members: 14063
Articles: 58,909
Categories: 202
Active Users: 392
Members: 0
Guests: 392
Bots: 327
Visits last 24h (live): 4782
Visits last 24h (bots): 11184

Latest Comments

This is a good and engaging article. A lot of information is beneficial to me, As AI slope continues to advance, these technologies will only become more powerful, heralding an era of innovation...
Thank you for sharing the very informative post.  Field Service Management Software
on Apr 10, 2024 about Advantages of Serverless Computing
While there may be a negative effect on some labor segments, robots and drift hunters automation increase productivity, lower production costs, and can create new jobs in the tech sector.
The distributors with the help of the medium work quite well in the industry  Washington Jackets